Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

New application of norcantharidin in drugs treating chronic glomerulonephritis

A technology for norcantharidin and glomerulonephritis, applied in the medical field, can solve the problems of unclear effect of renal interstitial fibrosis, poor compliance, and many side effects of chronic glomerulonephritis treatment, achieving no toxic side effects, reducing Proteinuria, good safety effect

Inactive Publication Date: 2017-09-22
THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0017] In order to solve the problem that there is still no ideal drug to delay renal fibrosis and renal failure, the present invention first applies the traditional Chinese medicine derivative norcantharidin, which is traditionally used in the treatment of liver cancer, colon cancer and other gastrointestinal tumor diseases in my country, to chronic glomerular The treatment of patients with nephritis, combined with the classic treatment of chronic glomerulonephritis drugs valsartan and tripterygium wilfordii in the treatment of chronic kidney disease, to solve the current drug treatment of chronic glomerulonephritis with many side effects, poor compliance and the effect on renal interstitial fibrosis Unclear and other technical issues

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • New application of norcantharidin in drugs treating chronic glomerulonephritis
  • New application of norcantharidin in drugs treating chronic glomerulonephritis
  • New application of norcantharidin in drugs treating chronic glomerulonephritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] The clinical trial of embodiment 1NCTD

[0043] Since the clinical trials on NCTD are still in its infancy, considering the safety of patients, it is currently used in combination with other drugs for the treatment of chronic glomerulonephritis, and a separate NCTD treatment group will be set up after the obvious curative effect is observed.

[0044] 1.1 Object

[0045] A single-center, randomized, parallel controlled method was used to select 64 patients aged between 18 and 55 years old, whose clinical diagnosis was consistent with chronic glomerulonephritis.

[0046] 1.2 Method

[0047] Patients were randomly divided into 2 groups according to their urine protein / creatinine ratio Up / Ucr: (1) the group with a urine protein / creatinine ratio of 0.2-0.95g / gcr, in which the control group received valsartan alone treatment (abbreviated ARB group), the treatment group was valsartan combined with norcantharidin treatment (abbreviated ARB+NCTD group); (2) the urine protein / u...

Embodiment 2

[0063] The mouse experiment of embodiment 2 NCTD

[0064] Renal fibrosis is one of the clinical symptoms of patients with chronic glomerulonephritis. At present, there is no ideal drug that can delay renal fibrosis and renal failure. The use of NCTD alone in the clinical treatment of patients with chronic glomerulonephritis remains to be studied. This example demonstrates the effect of NCTD on delaying renal fibrosis through mouse experiments, so as to further clarify the new application of NCTD in the treatment of chronic glomerulonephritis.

[0065] 2.1 Object

[0066] Take 18 C57BL / 6J male mice with a body weight of about 20-22g at 8 weeks, and divide them into 4 groups: normal group, unilateral ureteral ligation (UUO) group, unilateral ureteral ligation+low-dose norcantharidin intraperitoneal injection ( UUO+low-dose NCTD) group, unilateral ureteral ligation+high-dose norcantharidin intraperitoneal injection (UUO+high-dose NCTD) group.

[0067] 2.2 Method

[0068] The m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
retention rateaaaaaaaaaa
Login to View More

Abstract

The invention discloses new application of norcantharidin in drugs treating chronic glomerulonephritis. Traditional Chinese medicine derivative norcantharidin traditionally applied to treating gastrointestinal cancer diseases like liver cancer and colon cancer in China is applied to treating chronic glomerulonephritis, and is in joint use with classical drugs of valsartan and tripterygium wilfordii for treating chronic glomerulonephritis, the technical problems are solved that currently drugs for chronic glomerulonephritis have many curative side effects, poor compliance and an inaccurate effect on renal interstitial fibrosis, and a new treatment method is provided for clinically treating the chronic glomerulonephritis disease.

Description

technical field [0001] The invention relates to the field of medical technology, and relates to a new application of an antitumor drug-norcantharidin, in particular to a new application of norcantharidin in a drug for treating chronic glomerulonephritis. Background technique [0002] Chronic glomerulonephritis is currently the main cause of end-stage renal disease (ESRD) in my country. Proteinuria and renal interstitial fibrosis are important independent risk factors leading to its progression to ESRD. Therefore, reducing proteinuria and renal interstitial fibrosis is an important The key link to delay and block the progress of chronic glomerulonephritis [1-2] . At present, the commonly used clinical drugs for the treatment of chronic glomerulonephritis include glucocorticoids, immunosuppressants and RAAS blockers, etc. Although these drugs have a certain effect of lowering urinary protein, they have little effect on the treatment of renal interstitial fibrosis. Definite, a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/34A61P13/12A61K31/41A61K36/37
CPCA61K31/34A61K31/41A61K36/37A61K2300/00
Inventor 李瑛李军刘虹廖颖隽肖恒婷肖争
Owner THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com